ERBB2 and breast cancer: The monarcHER trial compared the efficacy of abemaciclib plus trastuzumab with or without fulvestrant to standard-of-care chemotherapy plus trastuzumab in advanced HER2-positive breast cancer in patients who had received at least two previous therapies [58].